JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

Search

Penumbra Inc

Open

SectorGezondheidszorg

252.56 11.46

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

225.25

Max

258.09

Belangrijke statistieken

By Trading Economics

Inkomsten

5.5M

39M

Verkoop

8.6M

324M

K/W

Sectorgemiddelde

211.907

38.156

Winstmarge

12.101

Werknemers

4,500

EBITDA

131K

49M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+36.2% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.9B

8.9B

Vorige openingsprijs

241.1

Vorige sluitingsprijs

252.56

Nieuwssentiment

By Acuity

50%

50%

157 / 375 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Penumbra Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jul 2025, 23:57 UTC

Acquisities, Fusies, Overnames

EQT: To Spend Y407.82B for Tender Offer

29 jul 2025, 23:56 UTC

Acquisities, Fusies, Overnames

EQT: Tender Offer Price Is Y5,700 a Share

29 jul 2025, 23:54 UTC

Acquisities, Fusies, Overnames

EQT To Start Tender Offer for Fujitec

29 jul 2025, 23:50 UTC

Marktinformatie

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 jul 2025, 23:36 UTC

Marktinformatie

Gold Steady Ahead of FOMC Decision -- Market Talk

29 jul 2025, 22:57 UTC

Marktinformatie

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 jul 2025, 22:50 UTC

Marktinformatie

Mondelez Warns of Price Increases in North America -- Market Talk

29 jul 2025, 22:44 UTC

Acquisities, Fusies, Overnames

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 jul 2025, 22:41 UTC

Acquisities, Fusies, Overnames

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 jul 2025, 22:41 UTC

Acquisities, Fusies, Overnames

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 jul 2025, 22:35 UTC

Winsten

IGO Maintains Nova Life of Mine Production Guidance

29 jul 2025, 22:35 UTC

Winsten

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 jul 2025, 22:35 UTC

Winsten

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 jul 2025, 22:34 UTC

Winsten

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 jul 2025, 22:34 UTC

Winsten

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 jul 2025, 22:34 UTC

Marktinformatie
Winsten

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 jul 2025, 22:33 UTC

Winsten

IGO Had A$279.7 Million of Cash at End-June

29 jul 2025, 22:33 UTC

Winsten

IGO 4Q Underlying Free Cash A$2.4 Million

29 jul 2025, 22:33 UTC

Winsten

IGO FY Sales Revenue A$512.5 Million

29 jul 2025, 22:33 UTC

Winsten

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 jul 2025, 22:32 UTC

Winsten

IGO FY Nickel Production 17,173 Tons

29 jul 2025, 22:32 UTC

Winsten

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 jul 2025, 22:32 UTC

Winsten

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 jul 2025, 22:31 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

29 jul 2025, 22:31 UTC

Marktinformatie
Winsten

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 jul 2025, 22:31 UTC

Winsten

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 jul 2025, 22:31 UTC

Winsten

IGO FY Spodumene Production 1.48 Million Tons

29 jul 2025, 22:30 UTC

Winsten

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 jul 2025, 22:30 UTC

Winsten

IGO 4Q Underlying Ebitda A$62 Million

29 jul 2025, 22:22 UTC

Winsten

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Peer Vergelijking

Prijswijziging

Penumbra Inc Prognose

Koersdoel

By TipRanks

36.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 313.5 USD  36.2%

Hoogste 330 USD

Laagste 283 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Penumbra Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

8

Buy

2

Hold

0

Sell

Technische score

By Trading Central

288.28 / 292.9394Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

157 / 375 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.